CalciMedica Inc. (NASDAQ:CALC) Short Interest Down 41.8% in July

CalciMedica Inc. (NASDAQ:CALC) was the target of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totaling 960,731 shares, a decrease of 41.8% from the June 30th total of 1,651,945 shares. Currently, 10.4% of the shares of the company are short sold. Based on an average daily trading volume, of 406,881 shares, the short-interest ratio is currently 2.4 days.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on CALC. Weiss Ratings reissued a “sell (e+)” rating on shares of CalciMedica in a report on Tuesday, July 7th. HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a research note on Wednesday. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

CalciMedica Stock Up 4.2%

Shares of NASDAQ:CALC traded up $0.03 during midday trading on Thursday, reaching $0.77. 89,323 shares of the company were exchanged, compared to its average volume of 1,112,996. The firm has a market cap of $12.23 million, a PE ratio of -0.58 and a beta of 0.89. The stock has a fifty day simple moving average of $0.82 and a two-hundred day simple moving average of $1.14. CalciMedica has a fifty-two week low of $0.46 and a fifty-two week high of $7.20.

Insider Buying and Selling at CalciMedica

In other CalciMedica news, Director Fred A. Middleton purchased 248,972 shares of the stock in a transaction on Thursday, June 25th. The shares were purchased at an average price of $0.80 per share, with a total value of $199,177.60. Following the acquisition, the director directly owned 1,063,272 shares of the company’s stock, valued at $850,617.60. This represents a 30.57% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 28.25% of the company’s stock.

Institutional Trading of CalciMedica

Hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC increased its holdings in CalciMedica by 45.0% during the first quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after buying an additional 39,775 shares during the last quarter. 180 Wealth Advisors LLC lifted its holdings in CalciMedica by 297.2% during the 1st quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after purchasing an additional 94,650 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in CalciMedica by 58.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after purchasing an additional 34,386 shares in the last quarter. Boothbay Fund Management LLC bought a new stake in shares of CalciMedica during the 4th quarter valued at $506,000. Finally, PVG Asset Management Corp bought a new stake in shares of CalciMedica during the 4th quarter worth approximately $302,000.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.